Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Sees Significant Decrease in Short Interest

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the recipient of a large drop in short interest in February. As of February 13th, there was short interest totaling 1,533 shares, a drop of 53.3% from the January 29th total of 3,281 shares. Based on an average trading volume of 5,511 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the shares of the stock are short sold. Approximately 0.0% of the shares of the stock are short sold. Based on an average trading volume of 5,511 shares, the short-interest ratio is presently 0.3 days.

Invesco Biotechnology & Genome ETF Trading Up 0.8%

Shares of NYSEARCA PBE traded up $0.64 during midday trading on Friday, hitting $81.98. 2,453 shares of the company’s stock were exchanged, compared to its average volume of 6,632. The business’s fifty day moving average price is $82.58 and its two-hundred day moving average price is $77.02. The company has a market cap of $263.16 million, a price-to-earnings ratio of 20.44 and a beta of 0.79. Invesco Biotechnology & Genome ETF has a 12-month low of $54.52 and a 12-month high of $85.73.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

A number of institutional investors have recently made changes to their positions in the stock. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 9,169.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock worth $28,175,000 after acquiring an additional 339,271 shares during the last quarter. Gerber Kawasaki Wealth & Investment Management raised its position in Invesco Biotechnology & Genome ETF by 4.2% during the second quarter. Gerber Kawasaki Wealth & Investment Management now owns 254,172 shares of the company’s stock valued at $16,292,000 after purchasing an additional 10,213 shares in the last quarter. LPL Financial LLC lifted its stake in Invesco Biotechnology & Genome ETF by 5.0% during the fourth quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock worth $7,994,000 after purchasing an additional 4,617 shares during the last quarter. United Capital Financial Advisors LLC bought a new stake in Invesco Biotechnology & Genome ETF during the third quarter worth about $5,946,000. Finally, Royal Bank of Canada boosted its holdings in shares of Invesco Biotechnology & Genome ETF by 22.3% in the 1st quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares in the last quarter.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.